US EditionFDA poses efficacy, safety questions over four cancer drugs ahead of two-day adcomm
Summary by Endpoints News
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
FDA poses efficacy, safety questions over four cancer drugs ahead of two-day adcomm
The FDA on Friday raised efficacy, safety and trial design issues surrounding three new cancer drug indications and one new cancer drug ahead of a two-day meeting of its Oncologic Drugs Advisory Committee next week ...
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
